1. Home
  2. RVYL vs MYNZ Comparison

RVYL vs MYNZ Comparison

Compare RVYL & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryvyl Inc.

RVYL

Ryvyl Inc.

HOLD

Current Price

$6.31

Market Cap

9.3M

ML Signal

HOLD

Logo Mainz Biomed N.V.

MYNZ

Mainz Biomed N.V.

HOLD

Current Price

$1.20

Market Cap

10.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVYL
MYNZ
Founded
2007
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
10.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RVYL
MYNZ
Price
$6.31
$1.20
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
N/A
$14.00
AVG Volume (30 Days)
838.4K
588.0K
Earning Date
11-14-2025
09-26-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,858,000.00
$659,935.00
Revenue This Year
N/A
N/A
Revenue Next Year
$297.49
$5.03
P/E Ratio
N/A
N/A
Revenue Growth
29.50
N/A
52 Week Low
$4.50
$0.92
52 Week High
$81.55
$8.20

Technical Indicators

Market Signals
Indicator
RVYL
MYNZ
Relative Strength Index (RSI) 65.03 50.40
Support Level $5.30 $1.15
Resistance Level $7.68 $1.37
Average True Range (ATR) 1.03 0.13
MACD -0.02 0.00
Stochastic Oscillator 39.58 22.12

Price Performance

Historical Comparison
RVYL
MYNZ

About RVYL Ryvyl Inc.

Ryvyl Inc is a technology company that develops, markets and sells blockchain-based payment solutions, which offers improvements to the payment solutions marketplace. Its focus is developing and monetizing disruptive blockchain-based applications, integrated within an end-to-end suite of financial products, capable of supporting a multitude of industries. Its proprietary, blockchain-based systems are designed to facilitate, record, and store a limitless volume of tokenized assets, representing cash or data, on a secured immutable blockchain-based ledger. It has two reportable segments North America and International. It generates the majority of its revenue from North America.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: